Shopping Cart
Remove All
Your shopping cart is currently empty
Abrocitinib (PF-04965842) (PF-04965842) is a potent, specific and orally-active JAK1 inhibitor (IC50s: 29/803 nM for JAK1/2).

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $77 | In Stock | In Stock | |
| 2 mg | $109 | In Stock | In Stock | |
| 5 mg | $170 | In Stock | In Stock | |
| 10 mg | $298 | In Stock | In Stock | |
| 25 mg | $491 | In Stock | In Stock | |
| 50 mg | $713 | In Stock | In Stock | |
| 100 mg | $927 | In Stock | In Stock | |
| 200 mg | $1,230 | Backorder | Backorder | |
| 1 mL x 10 mM (in DMSO) | $198 | In Stock | In Stock |
| Description | Abrocitinib (PF-04965842) (PF-04965842) is a potent, specific and orally-active JAK1 inhibitor (IC50s: 29/803 nM for JAK1/2). |
| Targets&IC50 | TYK2:1253 nM, JAK2:803 nM, JAK1:29 nM |
| In vitro | Abrocitinib inhibits IFN-stimulated phosphorylation of STAT1 in human whole blood (HWB), IFNα-stimulated phosphorylation of STAT3, as well as pSTAT5 in CD34+ spiked into HWB (JAK2), with IC50s of 163, 189 nM, 7.178 μM, respectively. |
| In vivo | In the rat adjuvant-induced arthritis model, Abrocitinib (5, 15, 50 mg/kg, p.o., daily for 7 days) significantly reduces paw swelling. |
| Synonyms | PF-04965842 |
| Molecular Weight | 323.41 |
| Formula | C14H21N5O2S |
| Cas No. | 1622902-68-4 |
| Smiles | CCCS(=O)(=O)N[C@H]1C[C@H](C1)N(C)c1ncnc2[nH]ccc12 |
| Relative Density. | 1.36 g/cm3 (Predicted) |
| Color | White |
| Appearance | Solid |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 120 mg/mL (371.05 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 4 mg/mL (12.37 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.